XOMA Corporation

About XOMA Corporation

XOMA Royalty is a biotech royalty aggregator that plays a unique role in helping biotech companies improve human health by acquiring economic rights to future milestone and royalty payments associated with pre-commercial clinical candidates. In return, sellers receive non-dilutive, non-recourse funding to advance their drug candidates.

Products & Services

Royalty Portfolio:An expansive portfolio of licenses providing rights to future potential royalty and milestone payments for drug candidate assets developed by others.

Royalty Acquisition:Actively acquiring rights to future potential milestone and royalty payments for pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies.

Assets Available for Licensing:Includes specific assets like Phage Display Platform, Ebopiprant, Anti-prolactin Antibody, and XMetA Portfolio available for licensing.

Specialties

Royalty Aggregation Biotech Financing Pre-commercial Therapeutic Assets Milestone and Royalty Payments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 140000000 MR: - FA: up to $140 million FAN: 140000000	D: 2023-12-19 FD: 2023-12-19	1 investors

Debt Latest

2023-12-19

$140.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack L. Wyszomierski

Chairman of the Board

H

Heather L. Franklin

Director

N

Natasha Hernday

Director

O

Owen Hughes

Chief Executive Officer, XOMA Royalty

B

Barbara Kosacz

Director

J

Joseph M. Limber

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News